CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-18 | Brumm Joshua T Chief Executive Officer | Sale 10b5-1 | −7,837 | $16.71 | $131K | 271,765 |
| 2026-09-18 | McNeill Jonathan President and COO | Sale 10b5-1 | −3,839 | $16.71 | $64K | 134,588 |
| 2026-09-16 | Lynch Ryan See Remarks | Sale 10b5-1 | −240 | $17.90 | $4K | 13,631 |
| 2026-09-16 | Pinkas Jan Chief Scientific Officer | Sale 10b5-1 | −658 | $17.90 | $12K | 21,581 |
| 2026-09-16 | Im Ellie Eunkyung Chief Medical Officer | Sale 10b5-1 | −623 | $17.90 | $11K | 21,446 |
| 2026-09-16 | Scalzo Richard William Chief Financial Officer | Sale 10b5-1 | −568 | $17.90 | $10K | 19,730 |
| 2026-09-16 | Bispham Barbara Harlin See Remarks | Sale 10b5-1 | −620 | $17.90 | $11K | 18,710 |
| 2026-09-16 | Brumm Joshua T Chief Executive Officer | Sale 10b5-1 | −1,610 | $17.90 | $29K | 279,602 |
| 2026-09-16 | McNeill Jonathan President and COO | Sale 10b5-1 | −731 | $17.90 | $13K | 138,427 |
| 2026-07-16 | Fairmount Funds Management LLC Director | Purchase | +853,450 | $14.50 | $12.4M | 3,601,316 |
| 2026-07-16 | Fairmount Funds Management LLC Director | Purchase · Pre-Funded Warrant (Right to Buy) | +525,897 | $14.50 | $7.6M | 2,294,037 |
| 2026-06-22 | Lynch Ryan See Remarks | Sale 10b5-1 | −465 | $17.99 | $8K | 13,871 |
| 2026-06-22 | Pinkas Jan Chief Scientific Officer | Sale 10b5-1 | −1,288 | $17.99 | $23K | 22,239 |
| 2026-06-22 | Scalzo Richard William Chief Financial Officer | Sale 10b5-1 | −1,112 | $17.99 | $20K | 20,298 |
| 2026-06-22 | Bispham Barbara Harlin See Remarks | Sale 10b5-1 | −1,218 | $17.99 | $22K | 19,330 |
| 2026-06-22 | Im Ellie Eunkyung Chief Medical Officer | Sale 10b5-1 | −1,219 | $17.99 | $22K | 22,069 |
| 2026-06-22 | McNeill Jonathan President and COO | Sale 10b5-1 | −20,549 | $17.99 | $370K | 139,158 |
| 2026-06-22 | Brumm Joshua T Chief Executive Officer | Sale 10b5-1 | −42,305 | $17.99 | $761K | 281,212 |
| 2026-06-02 | Violin Jonathan Director | Grant or award · Stock Option (Right to Buy) | +11,050 | 11,050 | ||
| 2026-06-02 | Lubner David Charles Director | Grant or award · Stock Option (Right to Buy) | +11,050 | 11,050 |
Page 1 of 16 · 305 trades